Medovate announces new agreement with Omneya Medical Co. to distribute SAFIRA™ device in Kuwait

23

UK based Medovate – a dynamic medical device development company specialising in anesthesia, airway management, critical care, and surgery – has today announced its first agreement in the Middle East with Omneya Medical Co. to distribute SAFIRA™ (SAFer Injection for Regional Anesthesia) in Kuwait.

Developed in collaboration with clinicians from the National Health Service (NHS) in the UK, SAFIRA™ is a revolutionary Class II medical device set to transform regional anesthesia around the world by making it a one-person procedure. 

It puts control of the injection in the hands of the anesthesiologist, freeing up other staff to carry out other tasks. The device also helps to improve patient safety by reducing the risk of nerve damage as it automatically limits injection pressure to less than 20psi.

Despite the ongoing global COVID-19 pandemic, which has resulted in strict border closures worldwide, Medovate has successfully secured a deal bringing the significant benefits SAFIRA™ provides to the regional anesthesia market in Kuwait.

One of the fast-growing companies in the country, Omneya Medical Co’s vision is to bring novel innovations to medical systems that support improvements in patient safety and care, a philosophy that aligns well with Medovate and the foundations on which SAFIRA™ was developed.  

Chris Rogers, Sales and Marketing Director, Medovate, commented: “Securing this agreement with Omneya Medical is a great achievement, and as our first distribution partner in the Middle East allows us to start positioning the many benefits SAFIRA™ brings to both patients and clinicians in Kuwait.”

Mr Jarrah Al Mutairi, Managing Director at Omneya Medical Co., added: “We are pleased to enter this strategic agreement with Medovate, which will be the beginning of further cooperation between our companies. I’m happy that clinicians and patients in Kuwait are the first in the Middle East to utilise the advantages offered by SAFIRA™ and I would like to thank the Medovate team for their efforts”.

SAFIRA™ has the potential to make a significant impact by turning regional anesthesia into a one-person procedure. Recent publications, including a joint statement by the American Society of Regional Anesthesia and Pain Management (ASRA) and the European Society of Regional Anesthesia and Pain Therapy (ESRA), have recommended regional anesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. This is because it preserves respiratory function and avoids aerosolization and the potential for transmission of COVID-19 compared to general anesthesia.

As demand for such procedures continues to grow steadily SAFIRA™ has the potential to make a significant impact in areas such as the Middle East, where the anaesthesia devices market is set to experience further growth in the next five years. 

Providing additional clinical advocacy in the Middle East is Consultant Anesthesiologist Dr Emad Fawzy, a co-inventor of SAFIRA™ who is currently based at the flagship Sheikh Khalifa Medical City in Abu Dhabi. He was previously based at the Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust in the UK as part of the team of clinical specialists behind the pioneering device. Medovate is dedicated to working closely with both the National Health Service (NHS) and clinicians in the UK to identify, develop and commercialize innovative medical devices with a focus on improving patient safety on a global scale. 

About Medovate:

Medovate is a medical device company dedicated to the development and commercialisation of innovative medical technologies created within the NHS and beyond. Medovate identifies and works with high potential medtech innovations, providing the specialist management and technical resources, along with finance required to lead innovation development through clinical trials and regulatory approval. By providing funding and support at a crucial point in the development of innovative medical technologies, Medovate accelerates innovations to market in order to benefit patient care and healthcare delivery. The company has a strong portfolio relating to specialisms in anaesthesia, airway management, critical care and surgery. Medovate directly benefits the NHS by: 

  • Providing access to funding, support and expertise to enable innovations created within the NHS to reach the market
  • Delivering commercial returns to the NHS organisations and inventors that created the technologies 

About Omneya Medical Co:

OMNEMED is a Kuwait based company specialized in distribution of medical equipment and supplies, collaboration with leading international partners to offer the latest technologies and solutions that satisfy the needs and requirements of healthcare sector through well trained professionals that are capable of supporting and delivering.

The Company provides wide range of products from different categories to satisfy customers needs in Ministry of Health, Private Hospitals, Medical Centres and Pharmacies.